drugset / Trial / NCT01189266

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

NCT01189266

Phase 1/2 Completed 79 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of vorinostat and to see how well it works when given together with radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with newly diagnosed diffuse intrinsic pontine glioma (a brainstem tumor). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vorinostat together with radiation therapy may kill more tumor cells.

Timeline

Start
2010-08-09
Primary completion
2017-06-30
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule 180 mg/m2 Oral
Subject Vorinostat Small molecule 230 mg/m2 Oral